ADRIADIANNISA YUNIAR MILASARI, 050710324 (2011) STUDI PENGGUNAAN ANTITOKSOPLASMOSIS PADA PASIEN TOKSOPLASMOSIS SEREBRAL Pada Pasien Rawat Inap di Unit Perawatan Intermediet Penyakit Infeksi RSUD Dr. Soetomo Surabaya. Skripsi thesis, UNIVERSITAS AIRLANGGA.

Preview	Text (ABSTRAK) gdlhub-gdl-s1-2012-milasariad-22389-ff3001-k.pdf Download (335kB) | Preview
	Text (FULLTEXT) gdlhub-gdl-s1-2012-milasariad-18706-ff3001-s.pdf Restricted to Registered users only Download (1MB) | Request a copy

Abstract

Cerebral toxoplasmosis is a life - threatening central nervous system (CNS) infection observed in advance HIV infection (AIDS) and oth er who had immunodeficiency caused by other factors. AIDS patients with cerebral toxoplasmosis not only got antiretroviral therapy but also antitoxoplasmosis therapy. The purpose of this study is to determine the pattern of antitoxoplasmosis usages in AIDS patients with cerebral toxoplasmosis who were hospitalized during March until June 2011. This research was descriptive analysis by using prospective data from patient’s medical record. This study has been done to find out the type, dose regimens and combi nation antitoxoplasmosis in AIDS patients with cerebral toxoplasmosis, to find out antitoxoplasmosis utilization with clinical and laboratories data, and to identify Drug Related Problem which related to drug interaction. The researcher got 11 AIDS patient s data with Cerebral toxoplasmosis and it’s known that every patient got initial antitoxoplasmosis such as pyrimethamine loading dose on the first day followed by pyrimethamine maintanance dose added by clindamycin and leucovorin as folic acid (100%). Init ial antitoxoplasmosis is given by CD4 data (63.6%), a positive result of anti - toxoplasma IgG antibodies with anti - toxoplasmosis IgM antibodies were usually absent (81.8%), and result of CT scan or brain MRI with contrast that showed toxoplasmosis condition (72.7%). In some patients also received co - trimoxazole as prophylaxsis (36.36%), Nystatin (90.91%), dexamethasone (72.73%) and phenytoin (27.27%). Outcome therapy can be seen from patient clininal impairment of conciousness (63.64%). The drug interaction that might be happened between antitoxoplasmosis and other drug which used on patient were found in this research but it was not observed in clinical setting.

Actions (login required)

View Item